Indication
Non-Small Cell Lung Cancer Stage III
4 clinical trials
3 products
1 drug
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial of CS1001 as Consolidation Treatment in Subjects With Locally Advanced/Unresectable (Stage III) Non-Small Cell Lung Cancer That Has Not Progressed After Prior Concurrent/Sequential ChemoradiotherapyStatus: Completed, Estimated PCD: 2023-04-03
Product
CS1001Clinical trial
Phase II Trial of Trastuzumab in Combination With Pertuzumab in Pretreated Patients With Non-small Cell Lung Cancer (NSCLC) Harboring a Her2 Mutation and Receiving DocetaxelStatus: Completed, Estimated PCD: 2021-02-01
Clinical trial
A Phase II Trial Evaluating Conformational Intensity Modulated Radiotherapy With Concomitant Nivolumab Followed by Nivolumab for Patients With Locally Advanced Non-small Cell Lung CancerStatus: Completed, Estimated PCD: 2023-04-15
Product
NivolumabClinical trial
A Randomised, Open, Blank-controlled, Multi-centre Study of Anlotinib as Sequential Therapy in Patients With Unresectable NSCLC(Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation TherapyStatus: Completed, Estimated PCD: 2021-11-11
Drug
PD-1 antibody